Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Bank of New Hampshire

Bank of New Hampshire reduced its position in Henry Schein, Inc. (NASDAQ:HSIC) by 87.2% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 2,199 shares of the company’s stock after selling 14,926 shares during the quarter. Bank of New Hampshire’s holdings in Henry Schein were worth $166,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Everett Harris & Co. CA increased its stake in Henry Schein by 29.1% in the 4th quarter. Everett Harris & Co. CA now owns 104,677 shares of the company’s stock valued at $7,925,000 after buying an additional 23,622 shares during the period. KBC Group NV increased its stake in Henry Schein by 163.5% in the 4th quarter. KBC Group NV now owns 521,964 shares of the company’s stock valued at $39,518,000 after buying an additional 323,901 shares during the period. Duality Advisers LP acquired a new position in Henry Schein in the 4th quarter valued at $1,561,000. Sprucegrove Investment Management Ltd. increased its stake in Henry Schein by 14.2% in the 4th quarter. Sprucegrove Investment Management Ltd. now owns 220,491 shares of the company’s stock valued at $16,693,000 after buying an additional 27,500 shares during the period. Finally, Pzena Investment Management LLC increased its stake in Henry Schein by 61.4% in the 4th quarter. Pzena Investment Management LLC now owns 809,558 shares of the company’s stock valued at $61,292,000 after buying an additional 307,934 shares during the period. 96.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on HSIC shares. Evercore ISI upped their price target on shares of Henry Schein from $79.00 to $83.00 and gave the stock an “in-line” rating in a research note on Wednesday, February 28th. Leerink Partnrs reaffirmed a “market perform” rating on shares of Henry Schein in a research note on Monday, February 26th. Piper Sandler reaffirmed an “overweight” rating and set a $86.00 price target on shares of Henry Schein in a research note on Friday. Barrington Research upped their price target on shares of Henry Schein from $90.00 to $92.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 8th. Finally, UBS Group lowered their price target on shares of Henry Schein from $82.00 to $80.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $81.73.

Henry Schein Price Performance

NASDAQ:HSIC opened at $67.26 on Friday. The firm has a market cap of $8.61 billion, a price-to-earnings ratio of 22.72, a price-to-earnings-growth ratio of 1.64 and a beta of 0.90. The company has a current ratio of 1.75, a quick ratio of 1.02 and a debt-to-equity ratio of 0.47. The company’s 50-day moving average is $70.44 and its two-hundred day moving average is $73.09. Henry Schein, Inc. has a 12-month low of $60.01 and a 12-month high of $82.63.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, May 7th. The company reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.09. The company had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.21 billion. Henry Schein had a net margin of 3.12% and a return on equity of 13.51%. The firm’s quarterly revenue was up 3.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.21 EPS. Research analysts expect that Henry Schein, Inc. will post 5.17 EPS for the current year.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.